HROW Earnings Date: Nov 9, 2026 (Estimated) — Harrow Health, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is HROW's next earnings date?
Harrow Health, Inc. (HROW) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.17 on revenue of $98.5M.
How did HROW do in its last earnings report?
In its most recent report on Aug 10, 2026 (Q2 2026), Harrow Health, Inc. posted EPS of -$0.46 versus the -$0.18 estimate, a miss of 91.7%. Revenue was $70.7M against a $70.4M estimate. The stock's 1-day post-earnings move was -3.1%.
How much does HROW stock move after earnings?
HROW beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 18.6% (up or down) in the day after earnings.
About Harrow Health, Inc.
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | Q2 2026 | -0.18 | -0.46 | -91.67% | $70.7M | ❌ Miss | -3.15% | -3.01% | -7.74% |
| 2026-05-11 | Q1 2026 | -0.35 | -0.74 | -111.43% | $44.2M | ❌ Miss | -23.69% | -18.77% | -5.63% |
| 2026-03-02 | Q4 2025 | 0.45 | 0.17 | -62.22% | $89.1M | ❌ Miss | -27.96% | -34.41% | -34.20% |
| 2025-11-10 | Q3 2025 | 0.22 | 0.33 | +50.00% | $71.6M | ✅ Beat | +13.47% | +18.01% | +47.04% |
| 2025-08-11 | Q2 2025 | 0.04 | 0.24 | +500.00% | $63.7M | ✅ Beat | +3.23% | +13.57% | +15.20% |
| 2025-03-27 | Q4 2024 | 0.13 | 0.40 | +207.69% | $66.8M | ✅ Beat | -5.96% | -13.67% | -11.55% |
| 2024-11-13 | Q3 2024 | -0.05 | -0.05 | +0.00% | $49.3M | ➖ Inline | -17.26% | -18.07% | -31.47% |
| 2024-08-07 | Q2 2024 | -0.07 | -0.06 | +14.29% | $48.9M | ✅ Beat | +54.32% | +68.56% | +72.79% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $70.7M total
| Segment | Share | Revenue | YoY | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 |
|---|---|---|---|---|---|---|---|
| Product Sales Net | 99.9% | $70.6M | — | — | — | — | — |
| Other Revenues | 0.1% | $90K | — | $68K | — | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.